{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125869","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.724237+00:00","generated_at":"2026-05-30T00:48:34.966255+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gyre Therapeutics Q3 2024 revenue down 20% to $25.5M; net income falls to $2.9M from $7.5M","bullets":["Revenue $25.5M in Q3 2024 vs $32.0M in Q3 2023, down 20% due to lower anti-fibrosis drug sales.","Net income $2.9M in Q3 2024 vs $7.5M in Q3 2023; nine-month net income $17.3M vs $15.5M.","Phase 3 trial for F351 in CHB liver fibrosis completed; topline data expected Q1 2025. US Phase 2 for MASH in 2025.","Commercial launches of avatrombopag (H1 2025) and nintedanib (2025) in China expected.","Cash and equivalents $15.9M as of Sept 30, 2024; funding runway over 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125869","json":"https://secwatch.observer/filing/0000950170-24-125869.json","markdown":"https://secwatch.observer/filing/0000950170-24-125869.md","text":"https://secwatch.observer/filing/0000950170-24-125869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/0000950170-24-125869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000095017024125869/gyre-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:48:34.966255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}